Important Update for Neogen Corporation Investors
As an investor in Neogen Corporation (NASDAQ: NEOG), it is essential to stay informed about recent developments that could significantly impact your financial interests. Recently, investors have been reminded of an important deadline concerning a class action lawsuit that may address losses incurred between specific dates.
What’s the Deadline?
Investors are encouraged to file a lead plaintiff motion by a defined date to join the class action associated with the decline in Neogen's stock value. Those who purchased shares during the designated period are advised to assess their positions and consider their options.
Overview of Recent Events
On January 10, 2025, Neogen revealed alarming financial results, reporting a substantial non-cash goodwill impairment charge related to its acquisition of the 3M Company. This information led to a significant revision in revenue forecasts and detailed weaknesses in its financial reporting processes, which understandably caused concern among shareholders.
Impact on Stock Prices
This disclosure prompted a considerable decline in Neogen's stock price, dropping 5.4% with the share value falling to $12.36. This sharp decline was a wake-up call for many investors as it signaled serious underlying issues within the company's operations.
Subsequent Disclosures and Further Declines
Continuing the troubling trend, an announcement on April 9, 2025, reported a further 3.4% decline in quarterly revenue as a result of ongoing integration issues post-acquisition. On that day, Neogen’s stock suffered even more, closing down by 28.7% to $5.02. This downward trajectory exemplifies the impact of integration difficulties and leadership changes within the company.
Current Expectation and Last Update
Neogen's most recent forecasts indicate that despite the challenging environment, the company expects EBITDA margins to stabilize around the high-teens. However, issues with elevated inventory write-offs continue to cast doubt on these projections, as evidenced by another drop in the stock price on June 4, 2025, which brought the shares down to $4.96.
Understanding the Lawsuit
The pending class action lawsuit claims that Neogen's management made misleading statements throughout the class period, which concealed material issues that have negatively affected investors. It entails allegations of failures to disclose financial weaknesses and inefficiencies inherent in its integration strategies post-acquisition.
How to Get Involved
If you hold shares of Neogen purchased during the class period, you may have the right to seek recovery for your losses. You can move to request appointment as lead plaintiff in this class action, which intends to address these serious allegations and potential compensations.
Contact Information
For additional information about the lawsuit or to learn more about your rights, please reach out to legal representatives. Specific details include:
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit addresses misleading statements made by Neogen's management during the specified class period, which may have impacted investors significantly.
When is the deadline to file a lead plaintiff motion?
The deadline to file is set for September 16, 2025. Investors must act before this date to participate in the lawsuit.
How can I participate in the lawsuit?
Investors who purchased Neogen shares during the class period can contact legal representatives to discuss their options for joining the lawsuit.
What caused the decline in Neogen's stock price?
The decline was primarily due to poor financial disclosures including impairment charges and decreased revenue forecasts, leading to investor losses.
Who can I contact for more information?
Investors can contact Charles Linehan at Glancy Prongay & Murray LLP for further details on participation and rights regarding the class action.
